⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
Analysis of aspirin's effects on colorectal cancer across five randomized trials with 20-year follow-up. Allocation to aspirin reduced colon cancer risk (HR 0.76, 95% CI 0.60-0.96) and mortality (HR 0.65, 95% CI 0.48-0.88), particularly for proximal colon cancers with ≥5 years of treatment. Doses of 75-300 mg daily showed benefit without requiring higher doses. Benefit increased with duration of treatment up to 20 years of follow-up.
Coeff. authors = avg(0.65, 1.00) = 0.83
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.83, 0.95) = 0.83← lowest dominates
Final coefficient : 0.83
Final score = 49.0/52.8 × 0.83 × 100 = 77/100
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
Eikelboom JW — 2017 · New England Journal of Medicine
Contrasted resultsCirculating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Th…
Tie J — 2019 · JAMA oncology
Contrasted resultsMeta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Hill A — 2021 · Open Forum Infectious Diseases
Contrasted resultsThrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Greinacher A — 2021 · The New England Journal of Medicine
Contrasted resultsEffect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Horby P — 2020 · The New England journal of medicine